Skip to main content
Top
Published in: Pediatric Nephrology 2/2010

01-02-2010 | Original Article

Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients

Authors: Tania Claeys, Maria Van Dyck, Rita Van Damme-Lombaerts

Published in: Pediatric Nephrology | Issue 2/2010

Login to get access

Abstract

Because tacrolimus (Tac) has a narrow therapeutic index and highly inter- and intra-individual variable pharmacokinetic (PK) characteristics, monitoring of drug exposure is recommended, but limited data are available on the kinetics of Tac in paediatric renal transplant recipients, especially of limited sampling strategies. To investigate the correlation between Tac trough level (TL) and the 0–12 h area under the curve (AUC), and the value of abbreviated AUC monitoring, we evaluated 12 h PK profiles in 27 children at least 1 year after transplantation. There was a significant discrepancy between Tac TLs and 0–12 h AUC (r = 0.60). Every time point, different from C0, gave a better prediction for the drug exposure, with C4 and C6 as best predictors (r = 0.93 and r = 0.92, respectively). The 0–12 h AUC was estimated with great precision by the use of a two- or three-point sampling strategy, and the latter is more time-point independent. In paediatric renal transplant recipients on Tac maintenance therapy, whose condition is stable, Tac TL is not a reliable tool for the estimation of drug exposure. Abbreviated monitoring, especially at three points in time, give reliable predictions of the complete 0–12 h AUC. We suggest a 0–12 h AUC of around 150 ng × h/ml for stable paediatric renal transplant recipients 1 year after transplantation and around 100 ng × h/ml in the following years. Target AUC values should be further established for paediatric transplant recipients according to the time after transplantation.
Literature
1.
go back to reference Conley SB, Flechner SM, Rose G, Van Buren CT, Brewer E, Kahan BD (1985) Use of cyclosporine in pediatric renal transplant recipients. J Pediatr 106:45–49CrossRef Conley SB, Flechner SM, Rose G, Van Buren CT, Brewer E, Kahan BD (1985) Use of cyclosporine in pediatric renal transplant recipients. J Pediatr 106:45–49CrossRef
2.
go back to reference Hardie IR, Tiller DJ, Mahony JF, Miach PJ, Thomson NM, Thatcher GN, Rigby RJ, Menzies BL (1993) Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine + prednisolone with cyclosporine + azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee. Transplant Proc 25:583–584PubMed Hardie IR, Tiller DJ, Mahony JF, Miach PJ, Thomson NM, Thatcher GN, Rigby RJ, Menzies BL (1993) Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine + prednisolone with cyclosporine + azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee. Transplant Proc 25:583–584PubMed
3.
go back to reference Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A (1989) K 506 for liver, kidney, and pancreas transplantation. Lancet 2:1000–1004CrossRef Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A (1989) K 506 for liver, kidney, and pancreas transplantation. Lancet 2:1000–1004CrossRef
4.
go back to reference Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S (1990) Kidney transplantation under FK 506. JAMA 264:63–67CrossRef Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, Johnston J, Iwaki Y, Jain A, Alessiani M, Todo S (1990) Kidney transplantation under FK 506. JAMA 264:63–67CrossRef
5.
go back to reference Wallemacq PE, Verbeeck RK (2001) Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40:283–295CrossRef Wallemacq PE, Verbeeck RK (2001) Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40:283–295CrossRef
6.
go back to reference Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, Grenda R, Vondrak K, Hughes D, Offner G, Griebel M, Brekke IB, McGraw M, Balzar E, Friman S, Trompeter R (2005) Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 9:498–503CrossRef Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, Grenda R, Vondrak K, Hughes D, Offner G, Griebel M, Brekke IB, McGraw M, Balzar E, Friman S, Trompeter R (2005) Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 9:498–503CrossRef
7.
go back to reference Filler G, Grygas R, Mai I, Stolpe HJ, Greiner C, Bauer S, Ehrich JH (1997) Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 12:1668–1671CrossRef Filler G, Grygas R, Mai I, Stolpe HJ, Greiner C, Bauer S, Ehrich JH (1997) Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 12:1668–1671CrossRef
8.
go back to reference Lee MN, Butani L (2007) Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation. Pediatr Transplant 11:388–393CrossRef Lee MN, Butani L (2007) Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation. Pediatr Transplant 11:388–393CrossRef
9.
go back to reference Armendáriz Y, Pou L, Cantarell C, Lopez R, Perelló M, Capdevila L (2005) Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 27:431–434CrossRef Armendáriz Y, Pou L, Cantarell C, Lopez R, Perelló M, Capdevila L (2005) Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 27:431–434CrossRef
10.
go back to reference Op den Buijsch RA, van de Plas A, Stolk LM, Christiaans MH, van Hooff JP, Undre NA, van Dieijen-Visser MP, Bekers O (2007) Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol 63:1039–1044CrossRef Op den Buijsch RA, van de Plas A, Stolk LM, Christiaans MH, van Hooff JP, Undre NA, van Dieijen-Visser MP, Bekers O (2007) Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol 63:1039–1044CrossRef
11.
go back to reference Derksen-Lubsen G, Van Steensel-Moll HA, Visser HK (2006) Compendium kindergeneeskunde diagnostiek en behandeling. Bohn Stafleu Van Loghum, Houten, p 325 Derksen-Lubsen G, Van Steensel-Moll HA, Visser HK (2006) Compendium kindergeneeskunde diagnostiek en behandeling. Bohn Stafleu Van Loghum, Houten, p 325
12.
go back to reference Kuypers D, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711–725CrossRef Kuypers D, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711–725CrossRef
13.
go back to reference Staatz CE, Willis C, Taylor PJ, Tett SE (2002) Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 72:660–669CrossRef Staatz CE, Willis C, Taylor PJ, Tett SE (2002) Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 72:660–669CrossRef
14.
go back to reference Filler G, Feber J, Lepage N, Weiler G, Mai I (2002) Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 6:411–418CrossRef Filler G, Feber J, Lepage N, Weiler G, Mai I (2002) Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 6:411–418CrossRef
15.
go back to reference Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V (2005) Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 9:162–169CrossRef Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V (2005) Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 9:162–169CrossRef
16.
go back to reference Shishido S, Asanuma H, Tajima E, Honda M, Nakai H (2001) Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 33:1066–1068CrossRef Shishido S, Asanuma H, Tajima E, Honda M, Nakai H (2001) Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. Transplant Proc 33:1066–1068CrossRef
17.
go back to reference Webb NJ, Stevenson PJ, Lewis MA, Postlethwaite RJ, Bradbury MG, Undre NA (2002) Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc 34:1948–1950CrossRef Webb NJ, Stevenson PJ, Lewis MA, Postlethwaite RJ, Bradbury MG, Undre NA (2002) Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc 34:1948–1950CrossRef
18.
go back to reference Montini G, Ujka F, Varagnolo C, Ghio L, Ginevri F, Murer L, Thafam BS, Carasi C, Zacchello G, Plebani M (2006) The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol 21:719–724CrossRef Montini G, Ujka F, Varagnolo C, Ghio L, Ginevri F, Murer L, Thafam BS, Carasi C, Zacchello G, Plebani M (2006) The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol 21:719–724CrossRef
19.
go back to reference Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW (2005) AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67:2440–2447CrossRef Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW (2005) AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67:2440–2447CrossRef
20.
go back to reference Kelles A, Herman J, Tjandramaga TB, Van Damme-Lombaerts R (1999) Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 3:282–287CrossRef Kelles A, Herman J, Tjandramaga TB, Van Damme-Lombaerts R (1999) Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr Transplant 3:282–287CrossRef
21.
go back to reference Knight SR, Morris PJ (2007) The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 83:1525–1535CrossRef Knight SR, Morris PJ (2007) The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 83:1525–1535CrossRef
22.
go back to reference Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, Heinsvig EM, Poulsen J (2002) C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 17:1487–1490CrossRef Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, Heinsvig EM, Poulsen J (2002) C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 17:1487–1490CrossRef
23.
go back to reference Opelz G, Döhler B (2008) Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 86:371–376CrossRef Opelz G, Döhler B (2008) Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 86:371–376CrossRef
24.
go back to reference Hesselink DA, Ngyuen H, Wabbijn M, Gregoor PJ, Steyerberg EW, van Riemsdijk IC, Weimar W, van Gelder T (2003) Tacrolimus dose requirement in renal transplant recipients is significant higher when used in combination with corticoids. Br J Clin Pharmacol 56:327–330CrossRef Hesselink DA, Ngyuen H, Wabbijn M, Gregoor PJ, Steyerberg EW, van Riemsdijk IC, Weimar W, van Gelder T (2003) Tacrolimus dose requirement in renal transplant recipients is significant higher when used in combination with corticoids. Br J Clin Pharmacol 56:327–330CrossRef
Metadata
Title
Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients
Authors
Tania Claeys
Maria Van Dyck
Rita Van Damme-Lombaerts
Publication date
01-02-2010
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 2/2010
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-009-1331-6

Other articles of this Issue 2/2010

Pediatric Nephrology 2/2010 Go to the issue